Skip to main content

Ana Luzarraga Aznar

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Ana Luzarraga Aznar

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Desarrollo de CEMARK-Px, un método in vitro para el diagnóstico objetivo y preciso del tipo y grado histológico del cáncer de endometrio en fluido uterino

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melek Denizli, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 278300
Reference: DTS23/00091
Duration: 01/01/2024 - 31/12/2025

xx

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Ana Luzarraga Aznar, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 177500
Reference: PI23/01470
Duration: 01/01/2024 - 31/12/2026

Recerca biomèdica en ginecologia

IP: Antonio Gil Moreno
Collaborators: Natalia Rodriguez Gómez - Hidalgo, Elena Suarez Salvador, Jose Luis Poza Barrasus, Vicente Bebia Conesa, Angel García Jiménez, Maria Asuncion Perez Benavente, Carina Masferrer Ferragutcasas, Eva Colas Ortega, Sabina Salicrú Riera, Anna Ruano Lopez, Fco Javier De la Torre Fdez de Vega, Montserrat Cubo Abert, Silvia Cabrera Diaz, Laura Mañalich Barrachina, Marta Rebull Santamaria, Mireia Armengol Alsina, Ana Luzarraga Aznar, Irene De la Calle Fuentes, José Luis Sánchez Iglesias, Melissa Bradbury Lobato, Beatriz Villafranca Magdalena, Melek Denizli, Paula Cabre Fernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01157
Duration: 01/01/2022 - 30/06/2025

MiMARK

IP: Eva Colas Ortega
Collaborators: Ana Luzarraga Aznar, Melek Denizli
Funding agency: EIT- European Institute of Innovation & Technolog
Funding: 161087.5
Reference: MIMARK_EITHEALTH2021
Duration: 01/01/2021 - 31/12/2022

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

José Luis Peiró Ibáñez

José Luis Peiró Ibáñez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Nina Borràs Agustí

Nina Borràs Agustí

Postdoctoral researcher
Transfusional Medicine
Read more
Pau Bravo Aubeso

Pau Bravo Aubeso

Suport Recerca.Tècnic superor FPII
IT / Information Systems
Digital Transformation and Quality Area
Read more
Laura Soler Colomer

Laura Soler Colomer

Predoctoral researcher
Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.